Clonal Myeloproliferative Disorders in Patients with Down Syndrome—Treatment and Outcome Results from an Institution in Argentina

SIMPLE SUMMARY: Around 30% of children with Down Syndrome (DS) will develop Transient Abnormal Myelopoiesis (TAM) and 20% of them will progress to Acute Myeloid Leukemia (AML), mostly Megakaryoblastic Leukemia (AMKL). The optimal balance between treatment intensity and treatment-related toxicity has...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennella, Carla L., Cassina, Tamara Muñoz, Rossi, Jorge G., Baialardo, Edgardo M., Rubio, Patricia, Deu, María A., Peruzzo, Luisina, Guitter, Myriam R., Sanchez de La Rosa, Cristian G., Alfaro, Elizabeth M., Felice, María S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265690/
https://www.ncbi.nlm.nih.gov/pubmed/35805057
http://dx.doi.org/10.3390/cancers14133286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265690/
https://www.ncbi.nlm.nih.gov/pubmed/35805057
http://dx.doi.org/10.3390/cancers14133286

Ejemplares similares